Ticker

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced today the appointment of Dr. Keith M.

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.

TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its…

Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform

New agreement is a significant commercial milestone and the Company's first with its contract research organization partner Agreement expands NetraMark's portfolio of AI-driven projects in central nervous system (CNS) disorders TORONTO, July 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial…